The FT Global Pharmaceutical and Biotechnology Conference, in its 35th successful year brought together life science companies, their health industry counterparts and emerging new industry entrants to review the key challenges facing the industry, and the business models and transformation strategies that will be needed to survive and thrive in the new era of unprecedented disruption and uncertainty.
FT Global Pharmaceutical and Biotechnology Conference 2017
Thriving Amid Uncertainty
UK Department of Health
With the Support Of
Days until event:
“This FT conference has become an annual leadership forum on the international stage, it’s a really important event for London and the UK.”
The Rt Hon George Freeman, Minister for Life Sciences UK
“The FT is always at the centre of what goes on in the industry. It’s a great source for all kinds of information and this conference for me is a great way to keep up with the trends and figure out what’s going on in the industry.”
Dr Flemming Ornskov, Chief Executive Officer, Shire
“Great conference to get an update on the strategic direction of global pharma from senior decision makers.”
Emily Lekkas, Scottish Development International
“A very relevant event for pharma/biotech, investors and industry observers.”
Guy Martin, The Pharma Letter
“The conference offers a tremendous opportunity to learn perspectives and insights on business models and medical value.”
Tim Durham, Takeda Pharmaceuticals
As old world certainties regarding payments, products and patients are swept away in a tidal wave of pricing pressures, growing geopolitical uncertainties and the new world realities of value, data and outcomes, life science companies will need to find new ‘ways to play’ if they are to adapt and compete in the new health economy which is emerging. Opportunities in the prevention, treatment and care of patients across key therapeutic areas including Alzheimer’s, cancer and other diseases of ageing, as well as the burgeoning field of precision medicine present opportunities, but can life science companies successfully play to their strengths in IP, regulation and high science to navigate the new terrain and ensure their place at the table?
James O’Shaughnessy is Parliamentary Under Secretary of State in the UK Department of Health. Previously he was a Senior Fellow at the Legatum Institute and a Senior Fellow at the Jubilee Centre for Character and Virtues at the University of Birmingham. In 2013, he founded Floreat Education, a Multi-Academy Trust of three primary schools in Wandsworth, Wokingham, and Brentford that deliver an ‘academics and character’ educational philosophy. He held a number of other education and advisory positions. Lord O’Shaughnessy was Director of Policy to David Cameron between 2010 and 2011. In that role, he was responsible for co-authoring the coalition's programme for government and overseeing the implementation of the government's domestic policy programme. He was Director of the Conservative Research Department from 2007 to 2010 and authored the Conservative Party's general election manifesto. He was made a life peer in 2015.
Karenann Terrell joined GSK as Chief Digital & Technology Officer in September 2017 with a company-wide remit to transform how new technologies are used to improve performance across the Group. She is a member of the Corporate Executive Team. She is responsible for GSK’s digital, data and analytics strategy, working with a wide range of partners from inside and outside the healthcare sector to bring new technologies to GSK, enhancing areas such as clinical trials and drug development; improving how the Group interacts with healthcare professionals, customers and consumers; and making internal processes more efficient. Ms Terrell’s previous role was Chief Information Officer for Walmart, where she led a multi-year effort to transform Walmart in the use of data, analytics and digital engagement with its customers. Prior to Walmart she was at Baxter International, where she was Chief Information Officer, and before that DaimlerChrysler. Ms Terrell began her career in General Motors and held various roles in manufacturing, engineering and brand management. She is a member of the board of trustees for the New York Hall of Science, a hands-on science and technology centre. She earned graduate and post-graduate degrees in Electrical Engineering from Kettering University and Purdue University, respectively.
Simon Stevens is CEO of NHS England, which leads the NHS’s work nationally to improve health and ensure high quality care for all. He is accountable to Parliament for over £100 billion of annual Health Service funding. Mr Stevens joined the NHS through its Graduate Training Scheme in 1988. As a frontline NHS manager he subsequently led acute hospitals, mental health and community services, primary care and health commissioning in the North East of England, London and the South Coast. He also served seven years as the Prime Minister’s Health Adviser at 10 Downing Street, and as policy adviser to successive Health Secretaries at the Department of Health. Alongside his 16 years work for the NHS and UK public service, Mr Stevens spent a decade working internationally at UnitedHealth Group, including as its Medicare CEO and as President of its global health division, leading health services in the United States, Europe, Brazil, India, China, Africa, and the Middle East. Mr Stevens was born in Birmingham and was educated at Balliol College, Oxford University; Strathclyde University, Glasgow; and Columbia University, New York where he was a Harkness Fellow at the New York City Health Department.
Viky Manaila, Managing Director at Trans Sped, is an international expert in the field of electronic signatures, digital identity and digitisation processes who has successfully promoted use of electronic signatures and electronic business processes throughout Europe and the US. She has been an advisor and technical expert to the European Commission for instituting Regulation 910/2014 (eIDAS) on electronic identity assurance and the design and roll-out of European, cross-nation e-procurement platforms and operations. Ms Manaila has detailed in-depth knowledge of regulations, technologies and policies in digitisation and digital identities in the EU and US, and has advised for over 10 years the global biopharmaceutical industry. She was involved from the very beginning in the SAFE-BioPharma projects established by the biopharmaceutical industry to speed its transformation to a fully electronic environment by using digital identity and electronic signatures. She has been involved recently in the high level working group set up by the European Commission and the US Government aimed at aligning policy and operations around trust identity, digital signatures and cross-recognition.
Belén Garijo is a Member of the Executive Board of Merck, a position she has held since January 2015. In this role, she is responsible for the Healthcare business sector, comprising the Biopharma, Consumer Health, Allergopharma and Biosimilars businesses. Since 2013 she also acts as President and CEO of the Biopharma business, where she started in 2011 as Chief Operating Officer. Before joining Merck, Dr Garijo was employed by Sanofi-Aventis as Senior Vice President Global Operations Europe, serving as a member of the Management Committee of the Sanofi-Aventis Group and of the Management Board of the Sanofi-Pasteur vaccines joint venture with MSD. In 2011, she took on the additional role of Global Integration Leader for the
Genzyme acquisition. From 2003 to 2006, Belén Garijo was General Manager of Aventis Spain, leading the merger of Sanofi-Aventis in 2004. From 2000 to 2003 she served as Global Vice President Oncology at Aventis and from 1996 as Director of the
Oncology Business Unit in the predecessor company Rhône-Poulenc Rorer. Prior to this she worked in R&D for eight years, initially as the Medical Director of the Abbott Laboratories Spanish affiliate, before moving to lead International Medical Affairs at the Abbott headquarters in Illinois, USA. Dr Garijo is a medical doctor, specialised in clinical pharmacology. She worked as a practicing physician for six years, before moving to the pharmaceutical industry.
Flemming Ornskov has been Chief Executive Officer at Shire since April 2013, after being appointed Chief Executive Officer Designate and a member of Shire’s Board of Directors in January 2013. Dr Ornskov brings to Shire extensive international, strategic and operational experience in the pharmaceutical sector, as well as medical expertise as a former pediatric intensive care physician. Prior to joining Shire, Dr Ornskov was Chief Marketing Officer and Global Head, Strategic Marketing for General and Specialty Medicine at Bayer from 2010 to 2012. Previous leadership roles included Global President, Pharmaceuticals and OTC at Bausch & Lomb Inc; Chairman, President and Chief Executive Officer of Life-Cycle Pharma A/S; and President and Chief Executive Officer of Ikaria, Inc. Earlier in his career Dr Ornskov served in roles of increasing responsibility at Merck & Co and Novartis AG following a distinguished period in hospital and academic medicine. He received his MD from the University of Copenhagen, MBA from INSEAD, and Master’s of Public Health from Harvard University.
Aubrey de Grey
Aubrey de Grey is Vice President of New Technology Discovery at AgeX Therapeutics, a subsidiary of BioTime, Inc developing new therapies in the field of biomedical gerontology. He is also the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. Additionally, he is Editor-in-Chief of Rejuvenation Research, a peer-reviewed journal from Mary Ann Liebert publishers focused on intervention in aging. His books include Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime (co-author, 2008, St. Martin’s Griffin) and The Mitochondrial Free Radical Theory of Aging (1999, R.J Landes), as well as numerous articles in peer-reviewed scientific journals. He has been interviewed by a variety of media outlets including The Economist, CBS’ “60 Minutes,” The New York Times, The Washington Post, Fortune, TIME and “The Colbert Report”. He received his BA in Computer Science and PhD in Biology from the University of Cambridge.
Beijia Ma is a Strategist on the Thematic Investing team at Bank of America Merrill Lynch in London. The team addresses long-term thematic issues both from an opportunity and risk perspective - including climate change, cybersecurity, education, energy efficiency, food security, longevity, millennials, obesity and health & wellness, pandemics, robots & AI, safety & security, waste, and water. The team publishes primers, quarterly Global Megatrend Primer Picks, and monthly Theme Watch reports. Prior to joining the Thematic Investing team, Ms Ma was an Equity Derivatives Trader at Bank of America Merrill Lynch in New York. She holds a BS with Honors in Biology from Stanford University.
David Meek was appointed Ipsen’s CEO in 2016, and also serves on the company’s Board of Directors. He joined from Baxalta Inc, where he was Executive Vice-President and President of the Oncology division. Prior to this, he spent 14 years in the US at Johnson & Johnson and Janssen Pharmaceutica, in senior commercial roles across multiple therapeutic areas in specialty and primary care. He also served as Chief Commercial Officer of Endocyte, an oncology biotechnology company in the US. Earlier in his career, Mr Meek was at Novartis for nine years, successively serving as a Global Business Franchise Head in Basel, Switzerland; President and CEO of Novartis Canada; and the Head of Oncology for Northern, Central and Eastern Europe based in Italy. Prior to his biopharma career, Mr Meek was an officer in the United States Army. He is a graduate of the University of Cincinnati.
Kemal Malik was appointed to the Board of Management of Bayer AG in 2014. He is responsible for Innovation across the Bayer group (pharmaceutical, crop science and consumer health). He has over twenty years of experience in the global pharmaceutical industry. He joined Bayer in 1995 and held positions of increasing responsibility in the Global R&D organisation. He was appointed Head of Global Development in 2003 within Bayer Healthcare, also becoming a member of the Executive Committee. In this role he was responsible for the advancement of Bayer’s pipeline across all therapeutic areas.
He initially joined Bristol-Myers Squibb, holding various positions in medical affairs and clinical development. Dr Malik studied medicine in London and subsequently spent several years at the Northwick Park Clinical Research Centre and at the Hammersmith Hospital, London.
Chief Technology Officer
GE Healthcare Life Sciences
Lorenz Mayr is Chief Technology Officer for GE Healthcare Life Sciences, a position he has held since May 2017. In this role, he is responsible for all R&D investments, research programmes, business growth strategy, technology innovation, and R&D talent development across all business areas (BioProcess, Imaging Diagnostics/Contrast Media, Research Tools and Applied Markets, Cell & Gene Therapy, New Opportunities).Prior to joining GE Healthcare Life Sciences, Mr Mayr was Vice President & Global Head, Reagents & Assay Development with responsibility for generation of biological reagents and assay development activities across all therapeutic research areas at AstraZeneca.
Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Office, and was appointed Chairman of the Board of Directors in 2015. Prior to joining Incyte, Mr Hoppenot was the President of Novartis Oncology, where he was responsible for translational medicine, development, approval and commercialisation, which included $11bn in global sales, the largest oncology pipeline in the industry, and a workforce of 8,000 employees in 50 countries. Mr Hoppenot joined Novartis in 2003 and, in addition to his role as President, served as Chief Commercial Officer, Head of Global Product Strategy & Scientific Development, and Senior Vice President, Head of Global Marketing. He started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the US Oncology business unit. Mr Hoppenot holds a Diploma from ESSEC Business School.
Mr Hogg joined Chi-Med in 2000, as its first employee, and has since led all aspects of the creation, implementation and management of the company’s strategy, business and listings. This includes the establishment of the company’s Innovation Platform, which now comprises eight clinical drug candidates, primarily in oncology, in over 30 clinical studies around the world and a scientific team of over 330 people based in Shanghai. Furthermore, the acquisition and operational integration of assets that led to the formation of the company’s Commercial Platform which manufactures and markets over 200 drugs through a team of over 3,300 marketing personnel covering over 300 cities and towns in China. Prior to joining Chi-Med, Mr Hogg spent ten years with P&G starting in the US in Finance and then Brand Management in the Laundry and Cleaning Products Division. Mr Hogg then moved to China to manage P&G’s detergent business followed by a move to Brussels to run P&G’s global bleach business. Mr Hogg received a Bachelor’s degree in Civil Engineering from the University of Edinburgh and an MBA from the University of Tennessee.
Samantha Budd Haeberlein
Samantha Budd Haeberlein, is Vice President Alzheimer’s Clinical Development at Biogen and is leading the team accountable for global clinical development for Biogen’s Alzheimer’s disease portfolio. Dr Budd Haeberlein, has more than 17 years of pharmaceutical industry experience across Research, Translational Science/Medicine and Clinical Development and is recognised internationally for leadership in Alzheimer’s disease drug discovery, diagnostics and clinical development. Prior to Biogen, Dr Budd Haeberlein was at AstraZeneca where she held roles in the US, Canada and Sweden as Vice President of Translational Science & Global Programmme Lead in Alzheimer’s disease. Dr Budd Haeberlein is a member of the World Dementia Council, and an Executive Member of the Board of The Boston Home. Dr Budd Haeberlein has a BSc and a PhD in Biochemistry from the University of Dundee in Scotland. She was a Wellcome Trust International Research Fellow and Instructor at Harvard Medical School as well as a Postdoctoral Research Associate at Children’s Hospital in Boston and conducted research at The Burnham Institute in San Diego.
Philip D. Gregory, D. Phil., has served as our chief scientific officer since June 2015. Philip was formerly with Sangamo BioSciences, where he held multiple leadership positions over a nearly fifteen-year tenure, most recently serving as chief scientific officer and senior vice president, research. In this role, he was responsible for the scientific direction and strategic research planning for the company. Philip played an integral role in Sangamo’s partnerships and drove early discovery and development for several IND candidates in multiple therapeutic areas. Prior to joining Sangamo, he was a postdoctoral fellow at Ludwig-Maximilians-Universität München. Philip holds a D. Phil in biochemistry from Oxford University, Keble College and a B.Sc. in microbiology from Sheffield University.
David Leather is Medical Vice President in the Respiratory Franchise at GlaxoSmithKline (GSK). He leads the Global Medical Expert team, a team of world renowned respiratory experts who work for GSK providing internal scientific and clinical expertise to support promoted medicines and those in development. For the last three years he led a team responsible for developing phase lll and phase lV trials for respiratory medicines. He also has a leadership role in “real world pragmatic trials” and is the Franchise leader of the internationally recognised Salford Lung Study. He joined GSK in 2000 and has held a variety of posts within the company. Originally a primary care physician in Bolton with an interest in respiratory disease, Dr Leather managed asthma and COPD clinics in a primary care setting and held a post as a clinical assistant in Respiratory Medicine at University Hospital Aintree in Liverpool. He was a GP Course Organiser, a member of the Council of the Royal College of GPs (RCGP), and worked as a media doctor for the BBC and commercial radio.
Vivek Ramaswamy is Founder and Chief Executive Officer of the Roivant Sciences family of companies. The Roivant Sciences family includes five wholly-owned or majority-owned subsidiaries, each focused on a different disease area: Axovant (neurology), Myovant (women’s health and endocrine diseases), Enzyvant (rare diseases), Dermavant (dermatology), and Urovant (urology). The group has 14 drugs in its pipeline and has raised over $2.5bn in capital to date to fund late-stage clinical programs and pursue adjacent business opportunities. Prior to founding Roivant, Mr Ramaswamy was an investor in the biotechnology sector. He currently serves as Chairman of the Board of Directors of Arbutus Biopharma Corporation and a member of the Board of Directors of Axovant Sciences, Myovant Sciences, and Roivant Sciences. He received an A.B. summa cum laude in Biology from Harvard College and a J.D. from Yale Law School.
Skills and experience: David Berman is Senior Vice President, Immuno-oncology (IO) Franchise at AstraZeneca and MedImmune, and is responsible for the strategy and oversight of all late stage IO programs. Previously he served as Senior Vice President and Head of the Oncology Innovative Medicines unit (iMED) at MedImmune, leading the cross-functional teams responsible for the strategy, growth, and advancement of the early stage oncology portfolio. Prior to joining MedImmune, Dr. Berman was Vice President and Head of the Immuno-Oncology Exploratory Development Team at Bristol Meyers Squibb and held various leadership roles in early and late-stage clinical development of the oncology portfolio after he joined in 2005. Dr. Berman was an attending pathologist at the National Cancer Institute of the National Institute of Health. A graduate of Massachusetts Institute of Technology, David earned his Ph.D. in the laboratory of Dr. Alfred Gilman at the University of Texas Southwestern Graduate School and his M.D. from the University of Texas Southwestern Medical School. He completed his residency in anatomic pathology at the National Cancer Institute and was pathology fellow at The Johns Hopkins Hospital. Dr. Berman is a widely published author with more than 40 journal articles.
Mike Nally is President of Global Vaccines at Merck & Co. With a $6bn vaccines business, the company is a global leader, providing a broad portfolio of paediatric, adolescent and adult vaccines to the world. In his role, Mr Nally aims to drive a dramatic increase in the reach and public health impact of vaccines, while delivering business growth. Prior to this appointment, Mr Nally led the company’s business in Sweden and the UK, focusing on the development and implementation of innovative, customer-centred approaches that delivered improved business results and accelerated patient access to the company’s products. Previously, Mr Nally was Executive Director of Strategic Initiatives and Operations at Merck & Co, and has also held positions in Finance, Business Development and Investor Relations. Mr Nally holds an MBA from Harvard Business School, a degree in Accounting and Finance from the London School of Economics, and a BA in Economics from Middlebury College, US.
Elie Lobel is the CEO of Orange Healthcare, the digital healthcare subsidiary of Orange Business Services. In this role, Dr Lobel is responsible for the strategic goals and vision of the Orange group in the healthcare sector with the aim of developing e-health activities in France and internationally by leveraging the Orange group’s vast expertise in information and communication technologies. Prior to joining Orange, Dr Lobel was Director of the National e-Health Projects division at ASIP Santé, a governmental agency responsible for promoting the deployment of e-health across France. During this period and through his responsibilities, Dr Lobel gained significant insight and solid knowledge of the various public policy issues relating to e-health. Throughout his career, Dr Lobel has consistently focused on the healthcare sector, with a particular emphasis on medical IT, e-health and medical imaging. He has significant experience in the start-up sphere, having contributed to the success of a number of innovative start-ups specialised in healthcare information systems and software-based medical diagnostics tools. Dr Lobel holds degrees in Engineering from the Ecole Centrale Paris and Cornell University (USA) and a PhD in Neuroimaging.
Othman Laraki is Co-Founder and CEO of Color. He spent several years at Google, where he worked on Google’s performance infrastructure and client-side software, including the Google Chrome browser. Following Google, he co-founded MixerLabs, which was acquired by Twitter in 2009. At Twitter, Mr Laraki was the Vice President of Product, helping create the company's first revenue products and grow the user base from 50 to 200 million users. Mr Laraki holds degrees in Computer Science and Management from Stanford University and the Massachusetts Institute of Technology. Mr Laraki is a long-time investor and advisor to leading companies such as Pinterest, AngelList, Slack, Instacart and others.
André Choulika is one of the founders of Cellectis and has served as Chief Executive Officer since the company's inception in 1999, and as Chairman of the Board of Directors since 2011. He has also served as President of Cellectis subsidiary company Calyxt since 2010. From 1997 to 1999, Dr Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children’s Hospital, where he was one of the inventors of nuclease-based genome editing technologies and a pioneer in the analysis and use of meganucleases to modify complex genomes. After receiving his PhD in Molecular Virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. His management training is from the HEC (Challenge +).
Ameet Nathwani was appointed as Executive Vice President, Group Chief Medical Officer and Global Head of Medical Function of Sanofi in May, 2016. Dr Nathwani is responsible for enterprise-wide medical, patient safety, medical quality assurance and ensuring the highest standard of transparency and compliance in Sanofi’s interactions with healthcare providers, patients and medical organizations. A UK. citizen, born in Uganda and educated in the UK, Dr Nathwani has more than 20 years of experience in the pharmaceutical industry beginning in 1994 when he joined Glaxo Group Research. From the period of 1994 to 2004 he held increasingly senior global functional and franchise leadership roles in research and development in Glaxo, SmithKline Beecham and GlaxoSmithKline, both in Europe and US. He joined Novartis in 2004 as the Senior Vice President and Global Development Head of the Cardiovascular and Metabolic Franchise and over a period of 11 years has held a number of senior development and commercial positions including the Global Head of the Critical Care Business Franchise. He was appointed as Global Head of Medical Affairs Novartis Pharma AG in June 2014 and became an extended member of the Pharma Executive Committee where he led the establishment of a Real World Evidence Center of Excellence and Digital Medicine capability. Dr Nathwani qualified in medicine in 1987 in London, acquired his specialization in Cardiology at a number of University Hospitals in London, and has a diploma in Pharmaceutical Medicine and an executive Masters in Business Administration.
Andy Schmeltz is a Senior Vice President and Head of the Patient & Health Impact Group at Pfizer. Bringing together experts in health economics and outcomes research, real-world data and analytics, patient-centered outcomes assessment, market access, pricing, strategy and contracting, the Patient & Health Impact Group develops solutions for increased patient access to Pfizer medicines and vaccines, and is working on broader business model innovation. In this capacity, Mr Schmeltz is leading Pfizer’s work to explore novel approaches to commercialise medicines through innovative partnerships and payment models. A 20-year veteran of the pharmaceutical industry, Mr Schmeltz started his career at Abbott Laboratories and joined Pfizer in 2003. During his tenure at Pfizer, Mr Schmeltz has held multiple leadership roles, including Chief Commercial officer for Pfizer Internal Medicine, where he was responsible for Pfizer’s $9bn global portfolio of medicines, as well as R&D strategy for cardiovascular metabolic, neuroscience and pain therapeutic categories. He also served as the North America Regional President for Pfizer Oncology. Under his leadership, Pfizer’s North America oncology business tripled in size. Mr Schmeltz serves on the board of National Pharmaceutical Council. He earned his BA in Economics from Columbia University and his MBA From the University of Chicago's Booth School of Business.
Régis Senegou is a Board Member of Sivan Innovation, a company that has developed
MoovCare, a medical software device used to detect cancer relapse or complications during the follow-up of lung cancer patients at high risk of relapse. Parallel to these activities, Mr Senegou is also the General Manager of Sephira, a leading player in electronic transmission of healthcare forms from healthcare professionals, and is involved, in the capacity of Chairman, in a number of other private health organisations.
Régis Senegou is a Board Member of Sivan Innovation, a company that has developed MoovCare, a medical software device used to detect cancer relapse or complications during the follow-up of lung cancer patients at high risk of relapse. Parallel to these activities, Mr Senegou is also the General Manager of Sephira, a leading player in electronic transmission of healthcare forms from healthcare professionals, and is involved, in the capacity of Chairman, in a number of other private health organisations.
Sir Kent Woods
Sir Kent Woods is Emeritus Professor of Therapeutics at Leicester University and Senior Medical Trustee and Vice-Chairman of the Board of Trustees of the British Heart Foundation. Prior to this, he served as Chairman of the Management Board of the European Medicines Agency 2011-2015, Chief Executive of the Medicines and Healthcare Products Regulatory Agency (MHRA) 2004-2013 and Director of the NHS Health Technology Assessment Programme 1999-2003. His earlier career was in cardiovascular medicine, conducting clinical trials and epidemiological studies in coronary heart disease. He is a Fellow of the Academy of Medical Sciences and was knighted for services to healthcare in 2011.
Joseph Antoun is Chairman and CEO of the Board of L-Nutra, Chairman of the Board at the Global Healthspan Policy Institute (GHPI), Director of Health Policy at University of Chicago and Editor-in-Chief of The Journal of Health Systems Reform. Dr Antoun’s work focuses on enhancing public health and human healthspan through advancing technologies that promote healthy aging and advocating for health policy reforms that support R&D, regulatory processes and increasing access to innovative healthspan technologies. Dr Antoun completed his studies in Health Policy at Harvard University, in Public Health at Johns Hopkins University, and in Medicine and Biological Sciences at Saint Joseph University.
Tauhid Ali is Vice President, Head TAK-celerator, Center for External Innovation at Takeda Pharmaceuticals International. Tauhid Ali serves as Vice President, Head Takeda TAK-celerator, a group focused on accelerating transformative therapies for people with rare diseases or indications where there remains a significant unmet need. The TAK-celerator is part of Takeda’s Center for External Innovation (CEI) organisation, adopting an incubator-like model to develop and externalise effective therapies. Its mission is to move assets through translation into novel therapies whereby externalisation paths, such as creation of new companies or collaborations with external partners, are made possible to increase the chances of reaching more patients. The TAK-celerator operates a very lean and entrepreneurial model primarily utilising external services and leveraging an extensive knowledge-based network. With more than 20 years international experience in the biopharmaceutical industry, Dr Ali has broad management and leadership experience in translational research, corporate strategy, global development and global project leadership. His work encompasses development of both small molecules and antibody therapeutics within a broad range of therapeutic areas, including oncology, autoimmune/inflammatory diseases, as well as orphan diseases. Dr Ali gained his PhD.from Cardiff University and a MSc in Clinical Sciences from the Welsh School of Pharmacy.
In 2010, Rolf Smeets was appointed Chief Medical Officer of Nutricia Advanced Medical Nutrition ,the medical nutrition business of Danone. Dr Smeets started his career in Research & Development in 1998 at Nutricia, leading nutritional research for disease management in oncology, cardiology and renal failure. In 2000, he led a research project in Sports Nutrition, and in 2002 was named Director of New Product Development for nutritional supplements company GNC in the USA. In 2003, Dr Smeets returned to The Netherlands as Director Medical Nutrition Research. Following the acquisition of Nutricia by Danone, Dr Smeets assumed responsibility for Research & Development for Danone’s Activia dairy brand. Dr Smeets obtained his PhD in Medical Sciences in 1998 from Radboud University in Nijmegen and holds an European Executive MBA from the University of Groningen.
Knut Slatten is a Senior Analyst at Moody’s, working in the Moody’s EMEA Corporate Finance Group. He is currently lead analyst for European pharmaceuticals and has covered European healthcare names for Moody’s since 2007. Prior to joining Moody’s, Mr Slatten worked as a credit analyst for Société Générale in Paris. Mr Slatten holds an MSc in Economics from the Norwegian School of Economics and Business Administration (NHH) and completed I a CEMS Master’s degree n Groupe HEC in Paris, France.
Bahija Jallal is Chief Executive Officer and Director of the Board of Immunocore, the leading T-Cell Receptor (TCR) biotechnology company. Prior to joining Immunocore in January 2019, she was President of MedImmune, Astra Zeneca’s global biologics research and development unit. She was also Executive Vice President of AstraZeneca and a member of its senior executive team. Dr Jallal serves on the Board of Anthem, Inc. and is a member of the Board of Trustees of the Johns Hopkins University and the Board of Directors of the University of Maryland Health Sciences Research Park Corporation. She also served as Chairman of the Board of Viela Bio in 2018. Dr Jallal has authored over 70 peer-reviewed publications and has more than 15 patents. She is a Council Member of the Government-University-Industry Research Roundtable of the National Academies of Sciences, Engineering and Medicine and a member of the American Association of Science. She is also the immediate past President of the Association of Women in Science. Dr Jallal was named the 2017 Woman of the Year by the Healthcare Businesswomen’s Association. Prior to joining MedImmune, Dr Jallal worked with Chiron Corporation where she served as Vice President, Drug Assessment and Development, and successfully established the company’s translational medicine group. Prior to Chiron Corporation, she worked at Sugen, Inc.Dr Jallal received a Master’s degree in Biology from the Universite de Paris VII in France, and her doctorate in Physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.
Sarah Emond leads the strategic planning and operations of the Institute for Clinical and Economic Review (ICER), a leading non-profit health policy research organisation, as Executive Vice President and Chief Operating Officer. In that role, she is responsible for overseeing ICER’s public programs, communications, operations, and finances.
Prior to joining ICER, Ms Emond spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company, and several years with a healthcare communications firm. She began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston.
A graduate of the Heller School for Social Policy and Management at Brandeis University, Ms Emond holds a Master of Public Policy degree with a concentration in health policy. She also received a Bachelor’s degree in Biological Sciences from Smith College.
Lisa Urquhart is editor of EP Vantage, a leading online news and analysis service covering the pharma, biotech and medtech industries. A journalist with more than a decade of industry experience, Lisa joined EP Vantage from the Financial Times, where she held a variety of positions, including biotechnology correspondent. Lisa is an active contributor to industry panels and articles and has commented on the pharmaceutical industry on both television and radio, focusing on business models, M&A and R&D strategies and innovation. In 2011 she was part of the EP Vantage team that won European Mediscience Commentator of the Year.
Stephen Moran is Global Head of Strategy for Novartis, a position he has held since January 1, 2017. Dr Moran joined Novartis in January 2015 as Strategic Assistant to the CEO. Prior to that, he was an Associate Principal at McKinsey & Company, serving as a leader in the healthcare practice. There his work focused on health system sustainability, research and development strategy and the economic analysis of clinical interventions across disease pathways. Dr Moran holds a Bachelor of Arts and a Master of Science in Natural Sciences from the University of Cambridge in the United Kingdom, and a doctorate in Biochemistry from the University of Oxford.
As Chief Executive Officer of Axovant, David Hung has a background that spans basic scientific research, clinical experience, entrepreneurial and business expertise, and creative passions. Previously, he was a Co-Founder, President and Chief Executive Officer of Medivation, Inc., until its acquisition by Pfizer Inc. in 2016 for $14.3bn. At Medivation, Dr Hung identified, in-licensed and led bench-to- bedside development of XTANDI, which is now the leading drug in the world for the treatment of advanced prostate cancer and qualifies for blockbuster status, having exceeded $2.2bn in global annual sales in 2016. Prior to that, Dr Hung served as Chief Scientific Officer and then as President and Chief Executive Officer at ProDuct Health, Inc. (which developed a minimally invasive microcatheter to procure cells from the breast milk ducts for the early detection of breast cancer and breast cancer risk assessment) until the acquisition of ProDuct Health, Inc. by Cytyc Corporation in 2001 for $168m.
Dr Hung received his A.B. in Biology and Organic Chemistry from Harvard College, and his MD from the University of California, San Francisco (UCSF) School of Medicine. He also completed clinical training in internal medicine, hematology, oncology, and transfusion medicine and then two basic science postdoctoral fellowships in brain tumor and cardiovascular research, all at UCSF School of Medicine.
Dr. Mason served as Head of Johnson & Johnson’s London Innovation Centre from October 2015 to April 2018, where he was responsible for Johnson & Johnson Innovation within the EMEA region. In this role, Dr. Mason led a team of transaction and scientific innovation experts to identify and develop a diverse portfolio of early-stage partnerships and investments across all three sectors of J&J.
Prior to joining J&J, Dr Mason was CEO of a venture-backed biotechnology startup, XO1 Ltd. until the company was acquired by Janssen Pharmaceuticals (a subsidiary of J&J) in March 2015. Prior to that, he was Head of Strategy and Business Development and member of Executive Leadership Team at specialty pharmaceutical and medical device company BTG Plc (LON: BTG), where he led its transformation into a leading interventional medicine company through multiple acquisitions including Ekos Corporation, Biocompatibles Plc, and MDS Nordion’s Therasphere business. Dr.Mason also served as an Executive-in-Residence for Advent Venture Partners where he served as a turnaround CEO for several portfolio companies. Prior to that he was Senior Vice President, Business Development at Cambridge Antibody Technology (CAT) and member of the CAT Executive Leadership Team.
Dr. Mason trained in Medicine at the St Bartholomew’s Hospital Medical College and worked in clinical practice in internal medicine before entering the biotechnology industry. He also has a degree in immunology from University College, London and an MBA from The Judge Business School, University of Cambridge, where he is currently a Fellow in Healthcare Management.
Sir Andrew Dillon
Andrew Dillon is Founder and Chief Executive of the National Institute for Health and Care Excellence (NICE), a position he has held since 1999. Prior to this, he held a number of senior management positions in the UK National Health Service, including General Manager of the Royal Free Hospital and Chief Executive of St George’s Healthcare NHS Trust, both academic medical centres in London. He graduated from the University of Manchester in 1975.
Stacy Lindau is Founder and Chief Innovation Officer of NowPow, and a practicing physician. Dr Lindau is also a tenured Professor at the University of Chicago, an expert in health of marginalised populations and communities, and is passionate about using the tools of science to engineer solutions to injustices that impede health. She is also Founder and President of the board of MAPSCorps, 501c3. Dr Lindau is an Aspen Institute Health Innovator Fellow and a member of the Aspen Institute Global Leadership Network.
Dr. Alex Zhavoronkov is the CEO of Insilico Medicine, a Baltimore-based leader in the next-generation artificial intelligence and blockchain technologies for drug discovery, biomarker development, and aging research. At Insilico, he pioneered the applications of generative adversarial networks and reinforcement learning techniques for generating the novel molecular structures with the desired properties. He set up R&D centres in six countries including Korea, Russia, and Taiwan and launched multiple biomarker initiatives including Young.AI. Previously, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI and established AgeNet.net competitions and Diversity.AI initiative. Since 2012 he has published over 80 peer-reviewed research papers and books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy”. He is also the co-organizer of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at EMBO/Basel Life, one of Europe's largest industry events in drug discovery. Dr. Zhavoronkov holds two Bachelor degrees from Queen’s University, a Master’s in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University.
Nicola Bedlington joined the European Patients’ Forum as its first Executive Director in June 2006. In this capacity, she is the Co-ordinator of the European Patient Academy on Therapeutic Innovation (EUPATI). From 2004 to 2006, she worked for the Swiss Government, leading the Environment and Schools Initiatives Secretariat (ENSI), an international government-based network set up by OECD focussing on innovation, action research and policy development in the field of Education for Sustainable Development. Whilst in Switzerland, she has also worked as an independent consultant/evaluator, specialising in European social and development policy and health advocacy. Ms Bedlington was the founding Director of the European Disability Forum, an umbrella organisation uniting over 70 European disability NGOs and National Councils of Disabled People to advocate for the human rights and inclusion of disabled citizens in Europe (1996 to 1999), and prior to this she worked as an external expert for the European Commission, heading the NGO unit within the HELIOS Programme, a European Commission Action Programme promoting equal opportunities for disabled people (1991-1996). Ms Bedlington studied Business and Human Resource Management in the UK and France.
Jason Langheier is the Founder and of Zipongo, a digital dietitian that connects people to a food buying platform for making cooking and restaurant selection easier, and free from the food maker advertising that has led to our obesity and chronic disease epidemics. Dr Langheier previously launched Boston Medical Center’s Nutrition and Fitness for Life paediatric obesity programme, founded Fitness Forward and the Coack K Drive 2 Fitness health education programme for low -income elementary-aged children and was the Co-Founder and Chief Technology Officer of Proventys, a developer of personalised cancer decision support, now part of US Oncology and McKesson. He studied Medicine, Biostatistics, and Clinical Research at Duke University School of Medicine, Harvard, and The University of California, San Francisco (UCSF) respectively, following neuroscience research at Williams College, Cambridge, Duke, and the National Institutes of Health (NIH).
José Luis Molinuevo
José Luis Molinuevo is the Scientific Director of the BarcelonaBeta Brain Research Centre of the Pasqual Maragall Foundation. His clinical work and research activities relate primarily to Alzheimer’s disease and associated disorders and he is currently focus in studying the preclinical stage of the disease and the development of prevention strategies. In addition to this role, he is also a researcher at the Institut D’Investigacions Biomèdiques August Pi I Sanyer (IDIBAPS), a member of the European Alzheimer Disease Consortium and the dementia panel for the European Association of Neurology, as well as the Alzheimer Biomarker Standardisation Initiative. Additionally, he is Spanish coordinator of the Biomarkers for Alzheimer’s and Parkinson’s Disease (BIOMARKAPD) group of the Joint Programming on Neurodegenerative Diseases, and Partner and Co-Lead of several Innovative Medicine Initiative consortiums, such as AETIONOMY, EPAD, AMYPAD. He also works with the International Working Group (IWG) and NIA-AA for developing new research criteria, and is a member of the AUC for CSF analysis working group. He has published over 220 international scientific papers, several books and over 20 book chapters on neurodegenerative diseases. He served on the board of directors of the Spanish Neurological Society from 2000 to 2002 and coordinated the dementia scientific group from 2006 to 2008. He was awarded with the ICGP international junior investigator award in 2003 and the AD scientific prize of the Spanish Neurological Society in 2010. His served as a physician at the University of Valencia, having received his neurology training at the Hospital Clinic de Barcelona. His PhD on Parkinson’s disease was completed at the University of Barcelona.
Sarah Haywood became Chief Executive Officer of MedCity in December 2015, having previously served as Interim CEO, and prior to that as Chief Operating Officer since MedCity’s launch in April 2014. She joined from London & Partners where she worked with Dr Eliot Forster to establish MedCity as a leading hub for life sciences research, development and commercialisation. Ms Heywood is a graduate of the NHS Management Training Scheme in Wales ,and worked in a number of NHS Trusts, including Great Ormond Street NHS Foundation Trust, before joining Novartis Pharmaceuticals Research as the Head of Operations for a neuroscience drug discovery unit located on the University ColleageLondon (UCL) campus. From there, Ms Heywood undertook a number of roles as a member of the Senior Civil Service, including leading the DTI (now BEIS) Bioscience Unit before it became part of the Office for Life Sciences. Her last role in BEIS was leading the design and legislation for the extension of the right to request flexible working and the shared parental leave system. Ms Heywood has a degree in Biology from the University of Oxford, a post graduate diploma in Management and an MA in Human Resources Management; she is a Chartered Fellow of the Chartered Management Institute.
Rod MacKenzie is Executive Vice President, Chief Development Officer for Pfizer. In this role, he is responsible for the development and advancement of Pfizer’s pipeline of medicines in several therapeutic areas, including cardiovascular and metabolic disease, inflammation and immunology, neuroscience, oncology and rare disease. He serves on the Portfolio Strategy and Investment Committee, which focuses on maximising the return on R&D investment across the Pfizer portfolio, and is a member of Pfizer’s Executive Leadership Team.
Dr MacKenzie joined Pfizer in Sandwich, UK as a Research Scientist. He is the co-inventor of darifenacin (Enablex™). Dr MacKenzie has held numerous leadership positions at Pfizer, including Head of PharmaTherapeutics Research and Development. He also served as Site Director of the Groton, Connecticut laboratories, Pfizer’s largest global R&D facility. Prior to this role, Dr MacKenzie held a series of research leadership positions, including Senior Vice President and Head of Worldwide Research, Head of Discovery Chemistry in Sandwich, UK, Head of the Discovery Technology Center in Cambridge, Massachusetts, Head of Discovery Research in Ann Arbor, Michigan, and Head of Drug Safety R&D.
Dr MacKenzie represents Pfizer on the Board of Directors for ViiV Healthcare, a global specialist HIV company established by GlaxoSmithKline and Pfizer to deliver advances in treatment and care for people living with HIV.Dr MacKenzie graduated from the University of Glasgow with a 1st Class Honours degree in chemistry and completed his PhD at Imperial College, London.
Carl Firth is Founder and Chief Executive Officer of ASLAN Pharmaceuticals. Under Mr Firth’s leadership, ASLAN has become Singapore’s first publicly listed biotech, completing an initial public offering in June 2017 with a listing on the Taipei Exchange. Previously, Mr Firth was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies across the region and advising on M&A transactions. Prior to joining the banking industry, he worked for AstraZeneca for 10 years in various commercial and R&D roles, including Regional Business Development Director, Asia Pacific, and Director of New Product Development, China. Mr Firth was chosen as one of SCRIP’s top 10 pharmaceutical leaders alongside notable industry veterans such as Ken Frazier, CEO of Merck, and Andrew Witty, CEO of GlaxoSmithKline. Mr Firth holds a PhD from Cambridge University in Molecular Biology (Trinity College), an Executive MBA from London Business School and a degree in Molecular Biology from Cambridge University .He is a member of Singapore’s Health and Biomedical Sciences International Advisory Council. He is also an Independent Director of Hong Kong listed Uni-Bio Sciences and Singapore’s Exploit Technologies, and is an Adjunct Professor at DukeNUS Medical School.
Andrew Hopkins is the Founder and CEO of Exscientia Ltd. Exscientia is an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery. Mr Hopkins is the author of some of the most highly cited papers in modern drug discovery. He spent ten years at the Pfizer, following his DPhil at the University of Oxford. Subsequently, he was one of the youngest professors when he was appointed to a Chair at the University of Dundee. Mr Hopkins has raised around £50m for commercial and academic research activities. He has won several awards for his work including the Royal Society of Chemistry’s Entrepreneur of the Year and the Capps Green Zomaya Medal, the BBSRC Commercial Innovator of the Year, Scottish Enterprise Life Science Entrepreneurial Leadership Award, and the Corwin Hansch Award. Mr Hopkins is a Fellow of the Royal Society of Edinburgh (RSE) , the Royal Society of Chemistry (RSC), the Royal Society of Biology (RSB) and the Learned Society of Wales (LSW) .
The NIHR Clinical Research Network is the research delivery arm of the NHS. It invests £300m each year into an infrastructure of clinical research professionals, to support recruitment into clinical research studies (over 725,000 participants in 2017/18).
A Director at the Network since 2014, Dr Cooper brings a wealth of experience to the post, having been part of the Network structure for a decade. Recently, Dr Cooper has also taken on the additional responsibility of Research Delivery Director.
In previous roles he was a member of the leadership team of the National Cancer Research Network and worked in the Clinical Research Group of AstraZeneca.
Jeremy Levin has served as Chief Executive Officer of Ovid Therapeutics since March 2015, and as Chairman of our Board of Directors since April 2014. Prior to joining Ovid Therapeutics, Dr Levin served as President and Chief Executive Officer, of Teva Pharmaceutical Industries Ltd, a publicly held pharmaceutical company, from 2012 to 2013. Dr Levin joined Teva in 2012. From September 2007 to December 2012, Dr Levin held several roles at Bristol-Myers Squibb, a publicly held pharmaceutical company, finally serving as the Senior Vice President of Strategy, Alliances and Transactions. Dr Levin also served as a member of the executive committee at Bristol-Myers Squibb. Prior to that, Dr Levin served as Global Head of Strategic Alliances at Novartis Institutes for Biomedical Research, Inc, a division of Novartis AG, from 2002 to 2007. Previously, he served on the board of directors of various public and private biopharmaceutical companies, including as Chairman and Chief Executive Officer of Cadus Pharmaceuticals Corporation, a drug development company. Dr Levin currently serves on the board of directors of BioCon Ltd., a publicly held biopharmaceutical company, Lundbeck (OMX: LUN), and ZappRx, Inc, an e-health company. Dr Levin is also a serving member on the board of the Biotechnology Innovation Organization. He has also served as a practicing physician at university hospitals in England, South Africa and Switzerland. Dr Levin earned his BA. in Zoology, MA in Cell Biology and PhD in chromatin structure, all from University of Oxford, and his MB and BChir from the University of Cambridge.
Dmitry Kaminskiy is is an innovative entrepreneur and investor who is a Co-Founder and a Senior Partner at Deep Knowledge Ventures, a Hong Kong based investment fund focused on disruptive DeepTech, AI, BlockChain, Cryptoeconomy, and the synergetic convergence of ultra-innovative technologies. In view of the significant growth of interest to the longevity industry, Deep Knowledge Life Sciences, a London-based subsidiary investment fund has increased its investment activity in 2017 and will actively expand its portfolio to catch the wave edge of the rising trend “Investing in Longevity”. In addition to his business experience, Mr Kaminskiy is involved in several scientific endeavours. He strongly believes that humans should live longer healthier lives. He has a major interest is anti-aging and healthy longevity which is reflected in his business, research and public activities. Mr Kaminskiy is well known for his support of life extension think-tanks in Oxford and Cambridge and many other non-profit activities. Mr Kaminskiy’s US$1 million prize for the first person to reach their 123th birthday went viral, and was widely covered by the world’s top media.
Prof. Adam Hill
Adam Hill is Chief Medical Officer of McLaren Applied Technologies. He is a dual-qualified clinician and mechanical engineer, with a career built at the interface of academia, industry and health systems. In recent years, he has founded a successful applied research centre, enveloping an R&D programme with expertise in the optimisation of novel products and systems, provided strategic advice to global life science companies on behalf of the British government, and led the medical function in a multinational, publically-listed health IT brand. In his current role at McLaren Applied Technologies, Professor Hill is focused on applying the company’s deep technical expertise to developing human-centric, data-driven solutions to challenging problems that inhibit the realisation of high quality health outcomes for all. Professor Hill has built a portfolio of over 100 publications, in addition to 12 academic awards and patents, and is a Visiting Professor in the Institute of Global Health Innovation at Imperial College London. Professor Hill graduated from Imperial College London as a medical doctor with gold medal; during this time, he also earned a PhD in Engineering and attended business school. Having subsequently graduated from the Royal Military Academy Sandhurst, he received his postgraduate clinical training from the Royal College of Surgeons of England, and professional engineering qualification from the Institution of Mechanical Engineers whilst Commissioned in the British Army.
Steve Cutler was appointed Chief Executive Officer of ICON plc in March, 2017, and serves on ICON’s Board of Directors. ICON is a global leader in the provision of outsourced development services to the pharmaceutical, biotechnology and medical device industries. Renowned for delivering excellence and innovation in the drug development process, ICON counts all of the world’s leading pharmaceutical and biotechnology companies amongst its customers. The company has particular expertise in helping transform pharma R&D through strategic partnerships and alliances. Dr Cutler joined ICON in 2011 as Group President, Clinical Research Services and was appointed Chief Operating Officer in January 2014, where he led ICON’s global operations, strategic customer alliances and the management of more than 460 clinical development projects from Phase IIb - IV. Dr Cutler has over 25 years of experience in the pharmaceutical and CRO industries. Prior to joining ICON, he was Chief Executive Officer of Kendle and oversaw the sale of the company to INC Research. Prior to Kendle, he held various operational and general management roles in both Quintiles and Sandoz (Novartis). Dr Cutler holds a BSc and a PhD from the University of Sydney and a Masters of Business Administration from the University of Birmingham.
Ulrich Mühlner is a senior healthcare executive with 17 years of industry experience. In 2016, he started GrowthCube Partners and became an active startup investor and entrepreneur to enable life-changing healthcare innovations by joining forces with scientists, innovators, and entrepreneurs, and - together - translating groundbreaking ideas, discoveries, and inventions into services and products that make a real difference to people’s lives. Dr Mühlner is particularly passionate about radically transforming the pharma industry through Big Data, Artificial Intelligence, and Deep Learning. In addition, Dr Mühlner is the CEO, Chairman and Co-Founder of docdok.health Ltd, a recently founded company with the mission to transform the quality, delivery and experience of medical care for both doctors and patients through its innovative cloud-based connected personalised health communication platform. He also serves as the CEO of E-Medicus Ltd. and globally as board member and advisor to biopharma and digital health/health tech companies, as well as international organisations and leading academic institutions. Previously, Dr Mühlner worked at Novartis and The Boston Consulting Group (BCG). At Novartis he served as Director and Head Global Corporate Strategy, Global Head Outcomes Technologies Incubator.In this role, he was responsible for the multi-billion dollar portfolio transformation strategy and spearheaded globally the digital health activities across Novartis leading to major digital health partnerships (Google/Verily, IBM, Proteus) with the aim to increase the value of the Novartis portfolio through ‘beyond-the-drug’ real-world outcomes solutions. In total, Dr Mühlner successfully executed deals with a volume of $350mn. Dr Mühlner studied Biochemistry in Hannover and Munich, and earned a PhD degree in Biochemistry and Molecular Biology based on his research on molecular mechanisms of cancer development at the Research Institute of Molecular Pathology (I.M.P.) in Vienna.
Lihi Segal co-founded DayTwo in 2015 to bring personalized health solutions based on the gut microbiome into the consumer mainstream. She is experienced in leading business and financial operations. Before starting DayTwo, she was COO and CFO of Sisense, a provider of business intelligence and analytics software. For more than fifteen years prior to that she has held senior roles in a number of businesses, from start-ups to large public enterprises. She is a certified Lawyer, with an LLB from the Tel-Aviv University, and has an MBA from Northwestern University, USA.
Deborah Waterhouse became Chief Executive Officer of ViiV Healthcare in April 2017. She brings a wealth of experience to ViiV Healthcare having lived and worked in Europe, Asia and the USA, and has a strong track record of performance in both specialty and primary care. She joined GSK in 1996 and was most recently the Senior Vice President of Primary Care within the company’s US business, prior to which she led the US Vaccines business. She also led the HIV business in the UK before heading the HIV Centre of Excellence for Pharma Europe, and held international roles as General Manager of Australia and New Zealand and Senior Vice President for Central and Eastern Europe.
Francesco De Rubertis
Francesco De Rubertis is Partner and Co-Founder of Medicxi. Prior to this, he was with Index Ventures for 18 years, having joined the firm in 1997 to launch its life sciences practice. While at Index life sciences, he spearheaded the creation and adoption of an asset-centric investment strategy and led the growth of the firm. At Medicxi he also oversees the firm’s operations. Among Dr De Rubertis’s investments are CellZome (acquired by GlaxoSmithKline), Egalet (NASDAQ: EGLT), GenMab (NASDAQ Copenhagen: GEN), GenSight Biologics (Euronext: SIGHT), Micromet (acquired by Amgen), Minerva Neurosciences (NASDAQ: NERV), Molecular Partners (Swiss: MOLN.SW), PanGenetics (acquired by Abbott), Parallele Biosciences (acquired by Affymetrix, NASDAQ: AFFX), Profibrix (acquired by The Medicines Company), and Versartis (NASDAQ: VSAR). Dr De Rubertis received a BA in Genetics and Microbiology from the University of Pavia and a PhD in Molecular Biology from the University of Geneva, and was then a postdoctoral scientist at the Whitehead Institute at MIT. He is a Chartered Financial Analyst and serves on the main board of the University of Geneva. Dr De Rubertis was named by BioWorld as one of 28 “movers and shakers” predicted to shape the biotechnology industry over the next two decades.
Colin Orford has 27 years of experience in the pharmaceutical sector gained at GSK (SmithKline Beecham), Novartis, Quintiles and Eisai which combines development strategy with operational execution. He has 20 years of drug development experience having led multiple R&D project teams, and has worked across all stages of the development spectrum from Phase 0 through to Phase IIIb. He has lead therapy area strategy teams in Alzheimer’s, multiple sclerosis, MDD and auto-immune disorders. Dr Orford has been responsible for transitioning multiple molecules, targeting MDD, Sleep disorders, Schizophrenia and Alzheimer’s Disease, from Phase 0, through proof of concept and, into late phase development. He has also led a number of Phase III teams and has been involved in several NDA and MAA submissions. Colin currently leads ICON’s Drug Development and Consulting services.
Kevin Pojasek is Vice President, Director of Corporate Strategy and a member of the executive leadership team at Immunocore. He is responsible for shaping the company’s corporate, R&D and growth strategies alongside members of the senior team and the board of directors. In addition, he is co-head of the company’s Infectious Disease Unit. Prior to joining Immunocore in 2016, Dr Pojasek was President and Chief Executive Officer of Quartet Medicine, a Cambridge, MA-based start-up discovering and developing novel treatments for chronic pain and inflammation. Under Dr Pojasek’s leadership, Quartet raised over $23m in Series A financing and entered into a strategic research partnership and option-to-acquire agreement with Merck for up to $595m. Dr Pojasek co-founded Quartet in late 2013 as an entrepreneur-in-residence at Atlas Venture. While working with Atlas, Dr Pojasek was also the Chief Operating Officer of Annovation Biopharma, a clinical-stage company developing novel intravenous anesthetics, which was sold to the Medicines Company in 2015. Dr Pojasek has also held senior executive R&D and corporate development roles at several venture capital-backed companies and, earlier in his career, spent time as an investment associate at PureTech Health (LSE: PRTC) an early stage venture capital. Dr Pojasek received his PhD from the Biological Engineering Department at Massachusetts Institute of Technology and his BA from the Molecular, Cellular and Developmental Biology Department at the University of Colorado, Boulder.
Henry Mahncke is the CEO of Posit Science, a position he has held since 2011. He joined the company at its inception in 2003 as Vice President of Research & Outcomes, leading the first large-scale clinical trials of a publicly available cognitive training program. Previously, he served as a science and technology advisor to the British government, and prior to that, as a consultant at McKinsey, focused on healthcare and video gaming. Dr Mahncke earned his PhD in Neuroscience at the University of California, San Francisco.
Ori Hershkovitz co-founded NEXTHERA Capital, a healthcare dedicated hedge fund, in 2015 and acts as its Chief Investment Officer. Mr Hershkovitz has 19 years of experience covering and investing in the healthcare sector. From 2006 to 2014, he was a founding member of the Sphera Global Healthcare Fund where he served as Head of Research. Prior to joining Sphera, he held several senior pharmaceutical equity analyst roles at Leader & Co (from 2001-2006) and at Ilanot Batucha Investment House (from 1998-2001). In the course of 2014, Mr Herhkovitz was the head lecturer for a healthcare analyst course sponsored by the Tel Aviv Stock Exchange, which was attended by leading investors and healthcare executives from across the globe. He earned a Bachelor's degree in Business Administration and Finance from Tel Aviv University.
Alexandra Eberhard is Managing Director, EMEA at Signals Analytics. Prior to joining Signals Analytics, Dr Eberhard was a Partner, Life Sciences at Cukierman & Co, where she led business development, fundraising and M&A initiatives. She also previously served as the Chief Executive Officer of Recogene, a biotechnology company engaged in the development of an asymmetric-specific-recombination technology platform utilised for the development of genetic disease therapies. Dr Eberhard holds a PhD in Immunology/Virology from BioMerieux. She completed her post-doctorate at the Weizmann Institute of Science and earned an MBA from Bar Ilan University. She has co-authored more than 15 peer-reviewed international publications and received 6 academic awards.
David Hodgson is the global lead of Deloitte’s Life Sciences Risk Advisory practice. He has over 20 years of life sciences consulting and advisory experience across multiple private and public sector clients. Mr Hodgson leads a number of Deloitte’s key risk, regulatory and commercial compliance programmes for Life Sciences clients and has worked extensively at board level across all areas of the regulatory and compliance agenda.
Christian brings a valuable mixture of clinical and business expertise to Mundipharma, having trained as a physician before joining management consultancy Bain & Company where he progressed to partner and head of the UK healthcare practice. He worked in the firm’s Boston, Zurich and London offices, leading assignments in strategy, M&A, technology/pipeline valuation, product launch, sales force effectiveness, turnaround and restructuring.
Christian heads Mundipharma’s European therapy area franchises, including pain, respiratory, biosimilars, oncology and addiction therapy. He is also responsible for the established brands business unit and market access in Europe.
He holds degrees and training from INSEAD (MBA), the University of Sydney, Australia (Med) and Boston University, US (BS and BSBA) and is fluent in five languages.
Vada Perkins is Managing Principal of IDENTIFICA, an independent global regulatory intelligence and life sciences IT practice with a wealth of knowledge and experience in regulatory science, international data standards, and Global Product Lifecycle Data Management (G-PLDM™).
Mr Perkins has extensive experience in the development, interpretation, and implementation of guidance, regulations, and international standards to support the comprehensive review of drugs, biologics, and devices throughout the product lifecycle. His expertise in regulatory science supports proactive collaboration with national and international stakeholders to harmonize regulatory activities in the development of innovative approaches to better assess the safety, efficacy, quality, and performance of medicinal products worldwide. Mr Perkins formally represented the US. and FDA as a Senior Advisor for Regulatory Science and Acting Deputy Associate Director for Review Management and worked in concert with leadership and staff on a broad range of regulatory and policy issues. He has comprehensive knowledge of product labelling and drug supply chain initiatives related to product/establishment identification, lot distribution, serialisation, falsified medicines, combination products, and unique device identification. He has received numerous awards which includes the FDA Commissioner’s Special Citation. Mr Perkins received his degrees from Johns Hopkins University, University of Southern California, and the University of Maryland-Baltimore.
Chairs and Moderators (3)
David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.
Mr Crow has an MA in English Literature from the University of Glasgow.
Sarah Neville began her career on local and regional newspapers, eventually becoming political editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. She joined the Financial Times in 2001 and has since held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and public policy editor in 2011. She was appointed Pharmaceuticals Correspondent in 2016.
Greg Reh is a Global Life Sciences & Health Care Industry Leader and the Global Life Sciences Sector Leader for Deloitte Touche Tohmatsu Limited (Deloitte). He is also the life sciences sector leader for Deloitte in the United States. He has more than 25 years of experience in the life sciences, process manufacturing, consumer and government sectors. His consulting career has spanned such topics as technology strategy, integration solution development and implementation of emerging and disruptive technology. His clients have included multinational pharmaceutical, biotechnology and chemical manufacturing organizations where he successfully led consulting services in support of regulatory, clinical, commercialization and manufacturing operations.
Prior to his consulting career Greg held positions at a government research lab, where he led teams in the design and development of life support devices; and was a lecturer at the University of Pennsylvania.
Agenda - 9th Nov
9:00amOpening Remarks from the Chair
Sarah Neville, Global Pharmaceuticals Editor, Financial Times
Simon Stevens, CEO, NHS England
9:25am‘Way to Play’: Embracing Strategic Opportunities in the New Health Economy
The recent history of pharma has been one of significant value destruction. Returns for shareholders look set to become in increasingly commensurate with those from commoditised industries – a position forecast only to intensify as pricing and other industry pressures start of bite. New ways to create value will need to be found if the industry is to continue to win favour with investors and strategies will need to be defined which will enable them to compete, to adapt and to embrace many of the new opportunities emerging in the new health economy. From novel science, high premium and digitally enhanced business models to strategies based on developing off-the-shelf IP acquired from big pharma, what are the ‘ways to play’ to create value and growth in life sciences? What are the risk and opportunities in the various approaches?
Session Keynote: Belén Garijo, Member of the Board, CEO, Healthcare, Merck
Kemal Malik, Member of the Management Board, Bayer
Jeremy Levin, Chairman and CEO, Ovid Therapeutics; Former CEO, Teva Pharmaceuticals
Ameet Nathwani Executive Vice President, Group Chief Medical Officer and Global Head of Medical Function, Sanofi
Christian Mazzi, Chief Commercial Officer & Managing Director, Established Brands, Mundipharma
Moderator: Sarah Neville, Global Pharmaceutical Editor, Financial Times
10:10amGetting the Big Picture: Geopolitical and Economic Risk - What Lies Ahead?
From the backlash against globalisation and its impact on trade and globally integrated supply chains to the decline in economic growth and structural challenges in emerging markets-what is the industry vulnerability to geopolitical risk, and the macroeconomic exposure it faces? What are the external forces currently at play which will add considerably to the industry’s exposure to risk? What lies ahead for US healthcare reform in the months and years ahead, and how are healthcare and life science companies addressing this uncertainty? What is the impact of Brexit and other potential disruptive political events in Europe - for instance, the impact on research, immigration, trade, IP, harmonisation of regulations, and HTA?
David Meek, CEO, Ipsen
Beijia Ma, Thematic Investment Strategist, Bank of America Merrill Lynch
Kevin Pojasek, Vice President, Director of Corporate Strategy, Immunocore
Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times
10:45amNetworking Coffee Break
11:00amCEO Keynote Interview
Vivek Ramaswamy, Chief Executive Officer, Roivant Sciences in conversation with David Crow
11:20amAdopting Open Innovation - Location, Strategies, Risks
Open innovation continues as a core strategy for life science companies in their drive to increase the productivity of their R&D. Location is key to the success of such efforts. For years, big pharma has been situated in fortress-like corporate campuses in places like New Jersey, Indiana and the Chicago suburbs. But increasingly, drugmakers are moving scientists to biotech clusters in coastal America and in Cambridge, UK. Here they can be close to the world's leading academic centres and younger drugmakers, guaranteeing access to early-stage science. What makes these "clusters" tick and what are the new hot areas to watch? Are clusters the best way to achieve enhanced collaboration? What are the opportunities, challenges and risks (e.g. IP) of open innovation? What are the lessons from early adapters and the outcomes?
Sarah Haywood, CEO, MedCity
Tauhid Ali, Vice President and Head,TAK-celerator, Centre for External Innovation (CEI), Takeda Pharmaceuticals International
Alexandra Eberhard, Managing Director, EMEA, Signals Analytics
Moderator: David Crow, Senior US Business Correspondent, Financial Times
11:55amRight - Sizing Regulation
As calls increase for a loosening of regulation, and the debate moves centre stage, speakers will discuss the pros and cons of less onerous regulation and drug approval. Are we seeing a politicisation of the debate regarding the drug approval process, with standards compromised and regulators ceding to patient pressures? As research breakthroughs continue to advance the boundaries of what’s possible in treatments, can we expect more coordinated campaigns as desperate patients strive to bend the regulatory rules rule in their favour? Or does regulation require a fundamental rethink? Should the focus be on safety, with efficacy left to doctors and patients?
Sir Kent Woods, Emeritus Professor of Therapeutics, Leicester University
David Hodgson, Leader, Global Life Sciences & Health Care Risk Advisory , Deloitte
Vada Perkins, Managing Principal, IDENTIFICA
Nicola Bedlington, Secretary General, European Patients’ Forum
Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times
Lord O'Shaughnessy, Parliamentary Under Secretary of State, UK Department of Health
1:55pmPricing and Access
Concerns regarding pricing and access remain central to the industry’s future profitability and sustainability. What are the emerging developments with regards to pricing, and potential solutions to the current impasse? Will self-regulation be sufficient? Will regulators, payers and patients continue to reward innovation?
Michael Nally, President, Global Vaccines, Merck & Co
Sir Andrew Dillon, Founder and CEO, National Institute for Health and Care Excellence (NICE)
Sarah Emond, Executive Vice President and Chief Operating Officer, Institute for Clinical and Economic Review (ICER)
Deborah Waterhouse, CEO, ViiV Healthcare
Moderator: Sarah Neville, Global Pharmaceutical Editor, Financial Times
2:35pmRealising the Potential of Real World Evidence (RWE)
As pharma companies continue to grapple with RWE, we hear from leaders in this field, who have developed end-to-end RWE capabilities, with insights into emerging best practice, and views on the remaining challenges in realising the full potential of RWE.
Andy Schmeltz, Senior Vice President, Patient & Health Impact Group, Pfizer
David Leather, Medical Vice President for Respiratory Franchise, GlaxoSmithKline
Matt Cooper, Business Development and Marketing Director, Clinical Research Network, National Institute for Health Research
Moderator: Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte
3:10pmNetworking Coffee Break
3:25pmTransforming Clinical Trials to Move Them to a 21st Century Paradigm
Rod MacKenzie, Executive Vice President, Chief Development Officer, Pfizer in conversation with Sarah Neville
3:45pmFocus on Cancer
Given recent high profile knockbacks in trial results, what is the outlook for the burgeoning immuno-oncology space? Will the hopes for solutions in cancer combination therapies be realised? What are the prospects and challenges for emerging cancer therapies, to include CAR-T? As the level of competition in cancer therapies increases, will the field become increasingly commoditised? How could a growing focus on prevention, rather than cure, impact financing and research on cancer?
André Choulika, Chairman and CEO, Cellectis
Christian Hogg, CEO, Chi-Med
Philip Gregory, Chief Scientific Officer, Bluebird Bio
David Berman, Senior Vice President, Immuno-oncology Franchise, AstraZeneca/MedImmune
Moderator: David Crow, Senior US Business Correspondent, Financial Times
4:25pmThe Trouble with Alzheimer’s: Transforming Treatment, Prevention and Care
Dementia - an ‘unstoppable epidemic, with Alzheimer’s at its core - is a leading cause of mortality in both the developed and developing world, and the enticing economics of aging populations is drawing growing numbers of in pharmaceutical and healthcare companies into finding solutions the improve the treatment, prevention and care of the disease. Yet progress has been slow, with no new treatment in a decade and recent drugs hailed to have promise failing in clinical trials. With the amyloid plaque theory now in doubt, is it time to evaluate alternative approaches, and which central theory is likely to guide further research efforts? Should the focus of research and investment now move to prevention? What are the innovations in diagnostics and technologies (e.g. robotics. AI, IoT, telecare etc.), prevention and care that could revolutionise the field?
Session Keynote: David Hung, CEO, Axovant Sciences
Amit Roy, Founding Partner, Foveal
Henry Mahncke, Chief Scientific Officer, Posit Science
José Luis Molinuevo, Scientific Director, BarcelonaBeta Brain Research Centre, Pasqual Maragall Foundation
Colin Orford, Senior Vice President, Drug Development Services and Consulting, ICON
Samantha Budd Haeberlein, Vice President, Alzheimer’s Clinical Development, Biogen
Moderator: David Crow, Senior US Business Correspondent, Financial Times
5:05pmInvestor Panel: How do the Markets View the Future for the Industry?
In this final session of the day, our panel of leading analysts and investors share their views on how they see the sector changing and the potential headwinds and opportunities ahead.
Ori Hershkovitz, Co-Founder and Chief Investment Officer, NEXTHERA Capital
Francesco De Rubertis, Co-Founder and Partner Medicxi
Knut Slatten, Vice President, Senior Analyst, Moody's Investor Service
Lisa Urquhart, Editor, EP Vantage
Moderator: David Crow, Senior US Business Correspondent, Financial Times
David Crow, Senior US Business Correspondent, Financial Times
Agenda - 10th Nov
9:00amOpening Remarks from the Financial Times
David Crow, Senior US Business Correspondent, Financial Times
9:05amCEO Keynote Interview
Flemming Ornskov, CEO, Shire in conversation with Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte
Our panel of strategists from leading pharma companies share their views on the megatrends ahead that have the potential to further transform the industry.
Lorenz Mayr, Chief Technology Officer, GE Healthcare Life Sciences
Stephen Moran, Global Head of Strategy, Novartis
Richard Mason, Head, Johnson & Johnson Innovation, EMEA
Carl Firth, Founder and CEO, Aslan Pharmaceuticals
Moderator: Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte
10:05amCEO Keynote Interview
Steve Cutler, CEO, ICON in conversation with Sarah Neville
10:25amHow Will Precision Medicine Transform Healthcare and Life Sciences?
Precision medicine - the tailoring of medicine and healthcare to a person’s individual’s genes, lifestyle and environment- is making steady inroads. But how can the full potential of precision medicine be better harnessed, and its economic model and utility enhanced? With the more accurate diagnostics and the more precise disease classification precision medicine enables, what are the implications for drug research and for healthcare systems currently built around disease - specific specialisations? As geneticists and computational experts take on a greater role, what will be the role for the physician? With more tailored and individualised treatments, will life science companies successfully embrace opportunities emerging along the ’patient journey’? With the transition to value-based care models expedite the uptake of precision medicine?
Hervé Hoppenot, President and CEO, Incyte Corp
Bahija Jallal, Executive Vice President, AstraZeneca and Head, MedImmune
Régis Senegou, Member of the Board, Sivan Innovation
Othman Laraki, Co-Founder and CEO, Color Genomics
Moderator: Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte
11:05amFood as Medicine
As an understanding of the link between food and health and the role of the microbiome grows, food companies are moving into the field of therapeutic and personalised nutrition. in doing so, they and behaving increasingly like drug companies through a focus on regulated products. What are the implications for life science companies? To what extent are these developments a threat or an opportunity to pharma? What are the prospects for personalised nutrition products based on gene/ biome type? Will food become a normal part of prescribing alongside pharmaceutical products?
Lihi Segal, Co-Founder and CEO, DayTwo
Jason Langheier, Founder and CEO , Zipongo
Rolf Smeets, Chief Medical Officer, Nutricia Advanced Medical Nutrition, Danone
Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times
11:35amNetworking Coffee Break
11:50amSocial Prescribing - The Next Big Thing?
With social prescribing playing an ever greater role in the medical professional’s toolbox, what are the implications for pharma? What is the evidence of the impact of social prescribing on health outcomes? Should health services pay? Will traditional drug based therapies and adherence be compromised, with detrimental impacts on health?
Stacy Lindau, Founder and Chief Innovation Officer, NowPow, in conversation with Sarah Neville
12:10pmAging and Longevity
A growing sum of company and investment capital is making its way into the study of aging with the aim not only of extending healthspan -but also of studying the link between the processes of aging with a view to halting the onset of and the many diseases which afflict old age to include Alzheimer's, heart disease and chronic diseases such as diabetes. What lies ahead could be a future in which aging could be viewed as just another disease to be ‘cured’, resulting in a less crippling and costly burden from age-related drug development and for care within the healthcare system. How far along are we in better understanding aging, and when might we see the testing and potential approval of anti-aging drugs in humans? What are the practical and philosophical challenges which need to be addressed before the development of anti-aging drugs arrives in earnest?
Dmitry KaminskIy, Co-Founder and Senior Partner, Deep Knowledge Ventures
Alex Zhavoronkov, CEO, Insilico Medicine
Joseph Antoun, Chairman & CEO, L-Nutra ; Chairman, Global Healthspan Policy Institute
Aubrey de Grey, Vice President of New Technology Discovery, AgeX Therapeutics
Moderator: David Crow, Senior US Business Correspondent, Financial Times
12:50pmOvercoming the Blocks of Digital Adoption in the Pharmaceutical Industry
Viky Manaila, Managing Director, Trans Sped-on behalf of Adobe Sign
1:10pmDisrupt or Be Disrupted: The Big Digital Debate
Will pharma companies flourish or flounder in the new digitised healthcare world? While pharma companies are recognising the value of digital products and services, their initiatives to date can appear as isolated beacons in a sea of change sweeping the healthcare industry. Will the industry be upended by data and consumer-savvy new entrants who are impinging even into the core R&D business of pharma? Or will pharma companies' traditional strengths in R&D, IP, risk management and complexity set them apart from the competition? Can they own and successfully navigate ‘the last mile’ to the customers and ensure their place as winners in the hew health economy ?
Karenann Terrell, Chief Digital & Technology Officer, GlaxoSmithKline
Adam Hill, Chief Medical Officer, McLaren Applied Technologies
Andrew Hopkins, Chief Executive Officer, Exscientia
Elie Lobel, CEO, Orange Healthcare
Ulrich Mühlener, Founder and Managing Director, GrowthCube Partners
Moderator: Greg Reh, Global Life Sciences and Health Care Industry Leader, Deloitte
1:55pmClosing Remarks from the Financial Times
Sarah Neville. Global Pharmaceuticals Editor, Financial Times
- Review the diverse strategies life science companies are adopting to position themselves for growth and to navigate the emerging value and outcomes terrain
- Debate the potential to greater cross-industry and cross-sector collaboration in the race for faster, cheaper, better cures
- Hear from those who are turning the vision of personalised medicine into a clinical reality for patients today, and their views on the challenges ahead
- Deep dive on the trouble with Alzheimer's and review the solutions to transforming treatment, prevention and care.
- Learn the latest on food as medicine - what is the opportunity and the challenge for pharma?
- Join the debate on how to right size regulation as the push for faster drug approval and less onerous regulation gains momentum
- Disrupt or be disrupted: as digital gains steam, will pharma flourish or flounder?
- Don’t get left behind - be part of a must-attend event mapping the continued transformation of healthcare
FT Live has a reputation for delivering very senior board level audiences to attend a wide range of world class thought-leadership events across the globe for nearly 40 years.
The FT Global Pharmaceutical and Biotechnology Conference will be attended by:
- Pharmaceutical companies
- Biotechnology companies
- Diagnostic and medical devices
- Healthcare providers and insurers
- Government healthcare departments, HTA’s and drug regulators
- Digital health companies
- Genomics and personalised medicine experts
- IT, big data and analytics providers
- Health economists
- Healthcare investment bankers, private equity and venture capitalists
- Healthcare lawyers and management consultants
- Patient representatives and NGOs
Presented By (1)
The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.
With the Support Of (1)
About Life Sciences and Health Care at Deloitte*
Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.
*Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (DTTL), a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity.
Lead Sponsor (4)
ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.
ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.
With headquarters in Dublin, Ireland, ICON currently, operates from 97 locations in 38 countries and has approximately 13,380 employees. For further information please visit www.iconplc.com Follow @iconplc on Twitter.
Funded by UK government, the National Institute for Health Research (NIHR) Clinical Research Network (CRN) is the clinical research delivery arm of the National Health Service (NHS) in England.
We support rapid study set-up and patient recruitment into all phases of clinical research studies, across all therapeutic areas. We’ve recruited over three million patients into clinical studies in the NHS over the last five years and created a thriving environment for conducting large scale commercial contract clinical research, so that companies can allocate clinical studies to the UK with confidence.
Last financial year:
- We supported more than 1200 commercial contract studies
- We recruited almost 35,000 patients into commercial contract studies
- 75% of the studies closing achieved 100% of their recruitment target within their planned timescales.
At the core of these successes is our Study Support Service - a package of free-of-charge services covering the life cycle of a clinical study including feasibility, set-up, costings and contracts, and performance monitoring to enable recruitment to agreed time and target. Come and see what we can do for you.
Phone: +00 44 (0)113 34 34 555
Signals Analytics (www.signals-analytics.com) is an Insights as a Service (IaaS) company that enables global life science brands to continuously experience the “aha moment” through Signals Playbook™ - a cloud-based augmented intelligence platform that transforms diverse, unstructured content into actionable business insights to maximize product portfolio health, accelerate new product development and propel breakthrough innovation. Leading life science companies have partnered with Signals Analytics to anticipate and react to change, optimize commercial decision making and drive superior business outcomes quicker and with less risk. Backed by Sequoia Capital, Qumra Capital, Pitango Growth and TPY Capital, Signals Analytics has been dubbed “The App Store for Innovation" by Forbes, was awarded Cool Vendor of 2016 by Gartner and has been honored the past two years as a Deloitte Fast 50 Technology Company.
Associate Sponsors (5)
Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data, insights, combined with personalised, expert client support.
Our online subscription services cover the pharmaceutical, biotech and medtech sectors.
EP Vantage our independent, award-winning editorial team offers data-driven, forward-looking news, commentary and analysis on a daily basis.
EvaluatePharma® delivers exclusive consensus sales forecasts and trusted commercial insight into biotech and pharmaceutical performance.
EvaluateMedTech® sets a new standard in commercial analysis and consensus forecasts of the global medical device and diagnostic industry.
EvaluateClinical Trials® delivers unique clinical trial intelligence expertly curated to efficiently analyse the global clinical trial landscape.
Evaluate Custom Services provides customised solutions to help you access, analyse and manage the information you need to support effective decision-making.
The Evaluate services enable the life science community to make sound business decisions about value and opportunity.
The Mundipharma global network of privately-owned independent associated companies (‘Mundipharma’) is equivalent to a mid-sized global pharmaceutical company. Central to our success is our focus on partnerships. We partner to accelerate the delivery of medicines to patients with unmet medical needs. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries, employing over 8,600 people.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. www.pfizer.com
TraceLink is the World’s Largest Track and Trace Network for connecting the Life Sciences supply chain, enabling real-time information sharing to improve patient outcomes and eliminating counterfeit prescription drugs from the global marketplace. Leading businesses trust the TraceLink Life Sciences Cloud to deliver complete global visibility, traceability and insights on medicines from ingredient to patient. A single connection to the Life Sciences Cloud enables a supply chain control tower for organisations that delivers the information and collaboration across the supply network needed to improve performance and reduce risk across global supply, manufacturing and distribution operations. A winner of numerous industry awards including Deloitte’s Technology Fast 500 (ranked number 149 in 2016), the Amazon AWS Global Start-Up Challenge Grand Prize, and the Edison Award for Innovation, TraceLink delivers solutions used by businesses across the globe to meet strategic goals in ensuring global compliance, fighting drug counterfeiting, improving on-time and in-full delivery, protecting product quality and reducing operational cost. TraceLink is headquartered in the United States with offices in Europe (London), India, and Singapore. For more information on TraceLink, visit www.tracelink.comor follow us on LinkedIn and Twitter.
Founded and led by CEO Jim Weiss in 2001, W2O is an independent network of complementary digitally-oriented marketing and communications firms focused on integrated business solutions to drive change and growth for the world's leading brands and organizations. W2O is built on insight integration, a strategic approach based on unearthing transformative insights and integrating them—across all marcom disciplines—for our clients’ brands. The goal is to create Unfair Advantage for our clients who face dramatic challenges in a shifting environment by following the right data to get to the solution. The right data clarifies your audience, what matters to them, and where your brand fits in their lives. W2O employs proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies and engagement to deliver sustained business results. W2O’s network includes WCG, Twist Mktg, Pure, Marketeching and Sentient, with a growing footprint of offices in the United States and Europe. For more information, please visit www.w2ogroup.com.
Supporting Partners (5)
The European Medical Journal is an independent, open-access eJournal dedicated to delivering first-class insights into ground-breaking changes, and advancements in medicine. Spanning sixteen therapeutic areas, including Innovations, Cardiology, Oncology, and more, each journal provides the reader with the latest medical congress highlights, abstract reviews, and peer-reviewed articles to name but a few of its wide content selection. Flagship EMJ journals are also published quarterly, bringing an assortment of research papers from a variety of topics.
European Pharmaceutical Review is the leading bi-monthly publication for information on technologies in drug discovery and manufacturing. Every issue offers a high level of technical and business contributions from the world's leading pharmaceutical companies and academic institutions, coupled with new and exciting features including interviews, updates and profiles.
Established in 1986, the Pharmafocus brand continues to be the most read and respected news portal in the pharmaceutical and biotech industry, with a team of dedicated journalists constantly updating the website; pharmafile.com, monthly newspaper Pharmafocus and daily e-newsletters with the latest quality global news, thoroughly researched analysis, market intelligence and high profile interviews. Covering important issues affecting the industry from the early stages of drug development, clinical trials, manufacturing, market access and global logistics.
PharmaBoardroom.com’s detailed country-specific reports - Healthcare and Life Sciences Review - deliver up an engaging mix of insight, opinion and market intelligence straight from the corporate boardrooms of some of the world’s most high performance economies.
Download our latest country report on
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 40 leading pharmaceutical companies, EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy. Our vision is for a healthier future for Europe. A future based on prevention, innovation, access to new treatments and better outcomes for patients.
222 Marylebone Road
London NW1 6JQ
United KingdomTel: +44 (0) 20 7631 8000